Revvity heads into Monday's earnings call with short interest down 4.6% over the past month and borrowing costs soft. Analyst sentiment has cooled sharply since February's post-earnings optimism gave way to April downgrades.
Short interest stood at 8.08 million shares as of April 23, representing 7.1% of the free float. That's down 4.6% from a month ago. Days to cover sits at 11.0 days. Cost to borrow is muted at 0.47%, down 7.5% over 30 days. Utilisation clocked in at 29.0% on April 23, well below the 52-week high of 39.1%. The data suggests limited short-side urgency heading into the print.
Put-call ratio collapsed to 1.11 on April 24 from a 20-day mean of 6.92. The current PCR sits 2.0 standard deviations below that mean, marking the most call-skewed sentiment in weeks. The 52-week range spans 0.08 to 10.05. The sharp tilt toward calls reflects either protective hedging or late-stage bullish positioning ahead of the event.
Consensus sits at buy, anchored by one Outperform rating. Mean price target is $113.93. Recent action has turned decidedly cautious. On April 14, Barclays downgraded RVTY to Equal-Weight from Overweight and slashed its target to $95 from $118. Goldman Sachs maintained Neutral the same day but lowered its target to $95 from $110. JP Morgan cut to $96 from $105 on March 31, holding at Neutral. Benzinga's bull case cites the TST-to-IGRA testing shift and Signals software growth as drivers of margin expansion. The bear case flags China revenue pressure and macroeconomic headwinds disrupting supply chains and customer demand.
P/E stands at 15.6, down 0.2 points over 30 days. EV/EBITDA sits at 13.1, down 1.0 from a month ago. Price-to-book is 1.27, nearly flat over the period. EPS momentum ranks in the 60th percentile on a 30-day and 61st percentile on a 90-day basis. Forward EPS growth sits in the 98th percentile. Dividend score ranks 95th. The company lacks momentum, quality, and value ML scores in the snapshot.
Insiders sold $6.5 million net over the past 90 days. CEO Prahlad Singh sold $663k on February 17. T. Rowe Price added 14.2 million shares in Q1, lifting its stake to 27.8%. Dimensional Fund Advisors added 486k shares, now holding 2.3%. Allspring Global bought 980k shares, reaching 1.6%.
RVTY last reported on February 2. The stock is down 7.7% over the past week and essentially flat over the past month at -0.8%.
No active ORTEX Alpha signals.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
